Search

Introduction Occlusal sealants in permanent molars demonstrate caries-preventive effects, lasting 15 to 20 years. (1,2) Dental sealants differ from restorative composite fillings. Unfilled pit and fissure dental sealants contain only [...], Purpose: This study examined the effects of a widely used (Delton® Pit & Fissure Sealant-Light Cure Opaque, DENTSPLY Professional, York, PA) pit and fissure sealant material on bisphenol A (BPA) levels in blood and saliva, among both low and high-dose groups over time. Methods: A convenience sample of 30 adults from the Old Dominion University population were randomly and evenly divided into 2 independent variable groups: a low-close group (1 occlusal sealant application) and high-close group (4 occlusal sealant applications). A 2 group, time series design was used to examine the presence and concentration of BPA in serum and saliva after sealant placement. Differences comparing low-close and high-dose groups were examined I hour prior (baseline), 1 hour post, 3 hours post and 24 hours after sealant placement, as measured by a direct-competitive BPA Enzyme Linked ImmunoSorbent Assay (ELISA). Hypothesized outcomes were evaluated by applying a parametric, 2 way ANOVA for repeated measures technique to data on the 30 participants ranging in age from 18 to 40 years, and were of mixed gender and ethnicity. Results: BPA was detected in the saliva of all participants prior to sealant placement and ranged from 0.07 to 6.00 ng/ml at baseline. Salivary BPA concentration levels peaked over a 3 hour period following sealant placement and returned to baseline levels within 24 hours. BPA was significantly elevated at all post-sealant placement time periods for both the low-dose (1 occlusal sealant application) and high-dose (4 occlusal sealant applications) groups with peak levels of 3.98 ng/ml and 9.08 ng/ml, respectively. The blood serum did not contain BPA at any point in this investigation. Conclusions: Exposure to BPA from sources other than dental resins contributes to salivary baseline concentration levels and indicates environmental exposure and use of products containing BPA. Use of specific molecular formulations of dental Sealant material determines the release of BPA, therefore, dental sealant materials should be reviewed independently when questioning the release of BPA from dental sealants. In addition, dosage amounts of the dental sealant material used in this study do not influence the serum concentration levels of BPA. Further research is needed to examine the cumulative estrogenic effects of BPA from dental sealants. Keywords: sealants, dental, bisphenol A, estrogenic This study supports the NDHRA priority area, Occupational Health and Safety: Investigate methods to decrease errors, risks and or hazards in health care and their harmful impact on patients.

Introduction:Tafasitamab (tafa) is a CD19-targeting immunotherapy indicated in combination with lenalidomide (len) for the treatment of adult patients with R/R DLBCL ineligible for autologous stem cell transplantation (ASCT). The 2020 FDA accelerated approval of tafa in this setting was based on findings from L-MIND, a multicenter, open-label, single-arm, phase 2 trial (Salles G, et al. Lancet Oncol.2020;21:978-988). Since this approval, there has been a paucity of real-world studies (RWS) evaluating the outcomes of patients with R/R DLBCL who received tafa in the community setting. We conducted this RWS to describe the patient characteristics, treatment patterns, and outcomes of patients who received tafa for R/R DLBCL across practice settings in the US.

Introduction:Tafa, a CD19-targeting immunotherapy, received accelerated approval by the FDA in combination with lenalidomide (len) for the treatment of patients with R/R DLBCL ineligible for autologous stem cell transplantation. In a recent real-world study (RWS) of tafa for R/R DLBCL, nearly one-third of patients were from typically underrepresented racial groups (abstract submitted to ASH 2023). Research has shown that patient characteristics, risk factors, and outcomes for DLBCL can differ by race and ethnicity (Li Y, et al. Cancer Epidemiol.2015;39:8-13; Ermann D et al. J Clin Oncol. 2022;40(suppl):7507). The purpose of this analysis is to understand the patient characteristics, treatment patterns, and outcomes observed in the tafa RWS by race and ethnicity.